Lemaitre Vasculr Stock Price, News & Analysis

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced preliminary Q2 2021 results, reporting net sales of $40.7 million, a 64% increase compared to Q2 2020, with organic growth of 35%. Operating income reached approximately $10.9 million to $11.3 million, up 128%. The gross margin declined to 65.5%-66.1%, impacted by inventory write-downs and manufacturing inefficiencies. Geographic sales growth was strong across all regions, especially in the Americas (+83%). Cash and cash equivalents stood at $21.8 million, while debt decreased by $9 million to $23 million.

LeMaitre Vascular (Nasdaq:LMAT) announced that President David Roberts will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on June 10, 2021, at 5:30 PM ET. The company specializes in devices, implants, and services for peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices tailored to vascular surgeons.

LeMaitre (Nasdaq:LMAT) announced the receipt of CE marks for five vascular products after a prior lapse due to a change in notified bodies. The newly certified products include XenoSure Biologic Patches, AlboGraft Polyester Vascular Grafts, and various Carotid Shunts, with expiration dates extending to 2024. Notably, the XenoSure's indications no longer cover neuro or cardiac applications. Andrew Hodgkinson highlighted that despite some product line losses totaling 3% of EMEA sales, customer supplies remained largely uninterrupted due to existing inventory.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will have its CFO, JJ Pellegrino, present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 1:30 PM EDT. The company specializes in devices and services for peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices aimed at vascular surgeons. For more details, visit www.lemaitre.com.

LeMaitre (Nasdaq:LMAT) reported Q1 2021 results showing sales of $35.9 million, a 17% increase year-over-year, despite a 5% organic decline. Net income reached $5.9 million, up 87%, with earnings per share of $0.28, also an 83% increase. Sales in the Americas and Asia/Pac grew significantly, while Europe/Middle East/Africa experienced a decline. The company declared a quarterly dividend of $0.11 per share, to be paid on June 3, 2021. For Q2 2021, LeMaitre projects sales between $37 million and $40 million, with a gross margin of 66.7%. Their share repurchase program has been authorized for up to $15 million.

LeMaitre Vascular announced its participation in two upcoming investor conferences in May 2021. David Roberts, President, will present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021. He will also be featured at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 9:00 AM EDT. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million people globally. The firm develops vascular devices tailored for vascular surgeons. More information is available at lemaitre.com.

LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its Q1 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and outlook. Interested parties can access the call via phone or a live webcast. LeMaitre is known for its vascular devices, addressing the needs of vascular surgeons and catering to a global patient base affected by peripheral vascular disease.

LeMaitre Vascular announced that CFO JJ Pellegrino will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 AM EDT. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million people globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For further information, visit www.lemaitre.com.

LeMaitre (Nasdaq: LMAT) reported strong Q4 2020 results, with sales of $37.5 million, a 24% increase year-over-year. Operating income surged 94% to $9.5 million, resulting in a net income of $7.0 million and earnings of $0.34 per diluted share. Debt was reduced by $21.5 million, improving the balance sheet. Despite gross margin slightly declining to 65%, the company achieved record sales driven by acquisitions and strong performance in the Americas. For Q1 2021, LeMaitre projects sales between $33.8 and $36.8 million, with an expected earnings per share of $0.24 to $0.31.